PAL-335

PAL-335 is a selective serotonin releasing agent (SSRA) which has been used in scientific research.^[1][2] It has been found to increase reward responsiveness (a prohedonic effect) in rodents similarly to the serotonin–norepinephrine–dopamine releasing agent and entactogen MDMA and the norepinephrine–dopamine releasing agent and stimulant 3-methylamphetamine (3-MA; PAL-314).^[1][2] The drug has also been found to impair task performance similarly to MDMA but unlike 3-MA.^[1][2] The interoceptive effects of PAL-335 in drug discrimination studies are being assessed.^[1][2] PAL-335 was first described in the scientific literature by Bruce E. Blough and colleagues in 2026.^[1] It is being used as a tool to help study the mechanisms underlying the rewarding effects and misuse liability of MDMA.^[1][2] The chemical structure of PAL-335 does not yet appear to have been disclosed.^[1][2]